

## DAFTAR PUSTAKA

- Alifieris, C., & Trafalis, D. T. (2015). Glioblastoma multiforme: Pathogenesis and treatment. In *Pharmacology and Therapeutics* (Vol. 152, pp. 63–82). Elsevier Inc. <https://doi.org/10.1016/j.pharmthera.2015.05.005>
- Ay, C., Dunkler, D., Pirker, R., Thaler, J., Quehenberger, P., Wagner, O., Zielinski, C., & Pabinger, I. (2012). High D-dimer levels are associated with poor prognosis in cancer patients. *Haematologica*, 97(8), 1158–1164. <https://doi.org/10.3324/haematol.2011.054718>
- Ay, C., Vormittag, R., Dunkler, D., Simanek, R., Chiriac, A. L., Drach, J., Quehenberger, P., Wagner, O., Zielinski, C., & Pabinger, I. (2009). D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. *Journal of Clinical Oncology*, 27(25). <https://doi.org/10.1200/JCO.2008.21.7752>
- Bestari, R., & Indra, S. (2020). Recurrent Glioblastoma Multiforme. *Jurnal Kesehatan Andalas*, 9(1S), 210–215. <https://doi.org/10.25077/jka.v9i1s.1176>
- Blionas, A., Giakoumettis, D., Klonou, A., Neromyliotis, E., Karydakakis, P., & Themistocleous, M. S. (2018). Paediatric gliomas: diagnosis, molecular biology and management. *Annals of Translational Medicine*, 6(12), 251–251. <https://doi.org/10.21037/atm.2018.05.11>
- Bobek, V. (2012). Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer? *Anti-Cancer Agents in Medicinal Chemistry*, 12, 0–000.
- Cabrini, G., Fabbri, E., Lo Nigro, C., Dehecchi, M. C., & Gambari, R. (2015). Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). *International Journal of Oncology*, 47(2), 417–428. <https://doi.org/10.3892/ijo.2015.3026>
- Chen, H., Thomas, C., Munoz, F. A., Alexandrescu, S., Horbinski, C. M., Olar, A., McGuone, D., Camelo-Piragua, S., Wang, L., Pentsova, E., Phillips, J., Aldape, K., Chen, W., Iafrate, A. J., Chi, A. S., Zagzag, D., Golfinos, J. G., Placantonakis, D. G., Rosenblum, M., ... Snuderl, M. (2019). Polysomy is

- associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. *Neuro-Oncology*, 21(9), 1164–1174. <https://doi.org/10.1093/neuonc/noz098>
- Cohen, R. B., Delord, J. P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R. L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., & Keam, B. (2018). Pembrolizumab for the treatment of advanced salivary gland carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, 41(11), 1083–1088. <https://doi.org/10.1097/COC.0000000000000429>
- Conti, A., Gulì, C., la Torre, D., Tomasello, C., Angileri, F. F., & Aguenouz, M. (2010). Role of inflammation and oxidative stress mediators in Gliomas. In *Cancers* (Vol. 2, Issue 2). <https://doi.org/10.3390/cancers2020693>
- Dimov, I., Tasić-Dimov, D., Conić, I., & Stefanovic, V. (2011). Glioblastoma multiforme stem cells. In *TheScientificWorldJournal* (Vol. 11). <https://doi.org/10.1100/tsw.2011.42>
- Driscoll, J. J., & Rixe, O. (2009). *Overall Survival: Still the Gold Standard Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials*. [www.journalppo.com](http://www.journalppo.com)
- Galvão, R. P., & Zong, H. (2013). Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression. In *Current Pathobiology Reports* (Vol. 1, Issue 1). <https://doi.org/10.1007/s40139-012-0006-3>
- Goldenberg, N., Kahn, S. R., & Solymoss, S. (2003). Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. *Journal of Clinical Oncology*, 21(22). <https://doi.org/10.1200/JCO.2003.05.165>
- Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme–Literature Review. *Cancers*, 14(10). <https://doi.org/10.3390/cancers14102412>
- Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017a). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pacific Journal of Cancer Prevention*, 18(1), 3–9. <https://doi.org/10.22034/APJCP.2017.18.1.3>

- Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017b). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pacific Journal of Cancer Prevention*, 18(1), 3–9. <https://doi.org/10.22034/APJCP.2017.18.1.3>
- Hasan, I., & Sekarutami, S. M. (2014). Standar Pengobatan Glioblastoma Multiforme. *Journal of the Indonesian Radiation Oncology Society*, 5(2), 51–60.
- Hayat, M. A. (2011). *Tumors of the Central Nervous System, Volume 1: Gliomas: Glioblastoma (Part 1)* (Vol. 1). Springer Science & Business Media.
- Hofer, S., Rushing, E., Preusser, M., & Marosi, C. (2014). Molecular biology of high-grade gliomas: What should the clinician know? In *Chinese Journal of Cancer* (Vol. 33, Issue 1, pp. 4–7). <https://doi.org/10.5732/cjc.013.10218>
- Hoke, M., Dieckmann, K., Koppensteiner, R., Schillinger, M., Marosi, C., & Mlekusch, W. (2011a). Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study. *Wiener Klinische Wochenschrift*, 123(7–8), 199–203. <https://doi.org/10.1007/s00508-011-1556-9>
- Hoke, M., Dieckmann, K., Koppensteiner, R., Schillinger, M., Marosi, C., & Mlekusch, W. (2011b). Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme – Results from a pilot study. *Wiener Klinische Wochenschrift*, 123(7–8), 199–203. <https://doi.org/10.1007/s00508-011-1556-9>
- Johnson, E. D., Schell, J. C., & Rodgers, G. M. (2019a). The D-dimer assay. *American Journal of Hematology*, 94(7), 833–839. <https://doi.org/10.1002/ajh.25482>
- Johnson, E. D., Schell, J. C., & Rodgers, G. M. (2019b). The D-dimer assay. *American Journal of Hematology*, 94(7), 833–839. <https://doi.org/10.1002/ajh.25482>
- Kathleen A.Kelly, John M. Kirkwood, D. S. K. (1984a). Glioblastoma multiforme: pathology, natural history, treatment. *Academic Press London*, 1–6.
- Kathleen A.Kelly, John M. Kirkwood, D. S. K. (1984b). Glioblastoma multiforme: pathology, natural history, treatment. *Academic Press London*, 1–6.

- Korshunov, A., Sycheva, R., & Golanov, A. (2006). Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). *Acta Neuropathologica*, 111(5), 465–474. <https://doi.org/10.1007/s00401-006-0057-9>
- Koshy, M., Villano, J. L., Dolecek, T. A., Howard, A., Mahmood, U., Chmura, S. J., Weichselbaum, R. R., & McCarthy, B. J. (2012). Improved survival time trends for glioblastoma using the SEER 17 population-based registries. *Journal of Neuro-Oncology*, 107(1), 207–212. <https://doi.org/10.1007/s11060-011-0738-7>
- Krex, D., Klink, B., Hartmann, C., Von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., & Schackert, G. (2007). Long-term survival with glioblastoma multiforme. *Brain*, 130(10). <https://doi.org/10.1093/brain/awm204>
- Kyriazi, V., & Theodoulou, E. (2013). Assessing the risk and prognosis of thrombotic complications in cancer patients. In *Archives of Pathology and Laboratory Medicine* (Vol. 137, Issue 9, pp. 1286–1295). <https://doi.org/10.5858/arpa.2012-0490-RA>
- Li, W., Tang, Y., Song, Y., Chen, S. H., Sisliyan, N., Ni, M., Zhang, H., Zeng, Q., Hou, B., Xie, X., & Chang, D. (2018a). Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. *Cellular Physiology and Biochemistry*, 45(4), 1663–1676. <https://doi.org/10.1159/000487734>
- Li, W., Tang, Y., Song, Y., Chen, S. H., Sisliyan, N., Ni, M., Zhang, H., Zeng, Q., Hou, B., Xie, X., & Chang, D. (2018b). Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. *Cellular Physiology and Biochemistry*, 45(4), 1663–1676. <https://doi.org/10.1159/000487734>
- Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. In *Acta Neuropathologica* (Vol. 131,

- Issue 6, pp. 803–820). Springer Verlag. <https://doi.org/10.1007/s00401-016-1545-1>
- Malueka, R. G., Dwianingsih, E. K., & Hartanto, R. A. (2022). *Glioma: Patofisiologi, Diagnosis, dan Tata Laksana* (S. Nurhayati & S. Safitri, Eds.). Gadjah Mada University Press.
- Mutmainna, A. I. S. (2017). *KARAKTERISTIK PASIEN ASTROSITOMA DI RSUP DR.WAHIDIN SUDIROHUSODO MAKASSAR PERIODE JANUARI – DESEMBER 2016*.  
[http://digilib.unhas.ac.id/uploaded\\_files/temporary/DigitalCollection/ODU4NzVmZjJhMDVjMDk1NWZwZDAwMjY1OTBiODU2MDA0YzA1YTg1Mw==.pdf](http://digilib.unhas.ac.id/uploaded_files/temporary/DigitalCollection/ODU4NzVmZjJhMDVjMDk1NWZwZDAwMjY1OTBiODU2MDA0YzA1YTg1Mw==.pdf)
- Nielsen, L. A. G., Bangsø, J. A., Lindahl, K. H., Dahlrot, R. H., Hjelmberg, J. V. B., Hansen, S., & Kristensen, B. W. (2018). Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. *Diagnostic Pathology*, 13(1). <https://doi.org/10.1186/s13000-018-0711-2>
- Onder, H., Kanyilmaz, G., Aktan, M., & Karahacioglu, E. (2018). Prognostic factors for survival in adult patients with grade II glial tumors. *Journal of Turgut Ozal Medical Center*, 1. <https://doi.org/10.5455/jtomc.2017.12.151>
- Ostrom, Q. T., & Barnholtz-Sloan, J. S. (2011). Current state of our knowledge on brain tumor epidemiology. *Current Neurology and Neuroscience Reports*, 11(3), 329–335. <https://doi.org/10.1007/s11910-011-0189-8>
- Parastuta, K. Y., Sriwidyani, N. P., Ekawati, N. P., & Saputra, H. (2020). GAMBARAN KLINIKOPATOLOGI TUMOR GLIA TAHUN 2014-2018 DI RSUP SANGLAH DENPASAR. *CEREBELLUM*, 9(7). <https://doi.org/10.24843.MU.2020.V9.i7.P02>
- Reavey-Cantwell, J. F., Haroun, R. I., Zahurak, M., Clatterbuck, R. E., Parker, R. J., Mehta, R., Fruehauf, J. P., & Brem, H. (2001). The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. In *Journal of Neuro-Oncology* (Vol. 55).
- Rossi, M., Gay, L., Ambrogio, F., Conti Nibali, M., Sciortino, T., Puglisi, G., Leonetti, A., Mocellini, C., Caroli, M., Cordera, S., Simonelli, M., Pessina, F., Navarria, P., Pace, A., Soffietti, R., Rudà, R., Riva, M., & Bello, L. (2021). Association

- of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. *Neuro-Oncology*, 23(5), 812–826. <https://doi.org/10.1093/neuonc/noaa225>
- Shu, Y. J., Weng, H., Bao, R. F., Wu, X. S., Ding, Q., Cao, Y., Wang, X. A., Zhang, F., Xiang, S. S., Li, H. F., Li, M. L., Mu, J. S., Wu, W. G., & Liu, Y. Bin. (2014). Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: A retrospective and in vitro study. *BMC Cancer*, 14(1). <https://doi.org/10.1186/1471-2407-14-566>
- Stark, A. M., Van De Bergh, J., Hedderich, J., Mehdorn, H. M., & Nabavi, A. (2012). Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients. *Clinical Neurology and Neurosurgery*, 114(7), 840–845. <https://doi.org/10.1016/j.clineuro.2012.01.026>
- Steinbrecher, K. A., Horowitz, N. A., Blevins, E. A., Barney, K. A., Shaw, M. A., Harmel-Laws, E., Finkelman, F. D., Flick, M. J., Pinkerton, M. D., Talmage, K. E., Kombrinck, K. W., Witte, D. P., & Palumbo, J. S. (2010). Colitis-associated cancer Is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin  $\alpha M\beta 2$  engagement of fibrinogen. *Cancer Research*, 70(7), 2634–2643. <https://doi.org/10.1158/0008-5472.CAN-09-3465>
- TAMIMI, A. F., & JUWEID, M. (2017). Epidemiology and Outcome of Glioblastoma. *Glioblastoma*, 143–153. <https://doi.org/10.15586/codon.glioblastoma.2017.ch8>
- Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic review of glioblastoma. In *Cancer Epidemiology Biomarkers and Prevention* (Vol. 23, Issue 10, pp. 1985–1996). American Association for Cancer Research Inc. <https://doi.org/10.1158/1055-9965.EPI-14-0275>
- Tian, M., Ma, W., Chen, Y., Yu, Y., Zhu, D., Shi, J., & Zhang, Y. (2018). Impact of gender on the survival of patients with glioblastoma. *Bioscience Reports*, 38(6). <https://doi.org/10.1042/BSR20180752>

- Walid, M. S. (2008). Prognostic Factors for Long-Term Survival after Glioblastoma. In *The Permanente Journal/ Fall* (Vol. 12, Issue 4). [www.emedicine.com](http://www.emedicine.com).
- Wang, P. F., Meng, Z., Song, H. W., Yao, K., Duan, Z. J., Li, S. W., & Yan, C. X. (2018). Higher plasma fibrinogen levels are associated with malignant phenotype and worse survival in patients with glioblastomas. *Journal of Cancer*, 9(11), 2024–2029. <https://doi.org/10.7150/jca.24714>
- Weitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017a). A Test in Context: D-Dimer. *Journal of the American College of Cardiology*, 70(19), 2411–2420. <https://doi.org/10.1016/j.jacc.2017.09.024>
- Weitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017b). A Test in Context: D-Dimer. *Journal of the American College of Cardiology*, 70(19), 2411–2420. <https://doi.org/10.1016/j.jacc.2017.09.024>
- Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., & Reifenberger, G. (2015). Glioma. In *Nature Reviews Disease Primers* (Vol. 1). Nature Publishing Group. <https://doi.org/10.1038/nrdp.2015.17>
- Wesseling, P., van den Bent, M., & Perry, A. (2015). Oligodendroglioma: pathology, molecular mechanisms and markers. In *Acta Neuropathologica* (Vol. 129, Issue 6, pp. 809–827). Springer Verlag. <https://doi.org/10.1007/s00401-015-1424-1>
- Witthayanuwat, S., Pesee, M., Supaadirek, C., Supakalin, N., Thamronganantasakul, K., & Krusun, S. (2018). Survival analysis of Glioblastoma Multiforme. *Asian Pacific Journal of Cancer Prevention*, 19(9), 2613–2617. <https://doi.org/10.22034/APJCP.2018.19.9.2613>
- Yeung, Y. T., McDonald, K. L., Grewal, T., & Munoz, L. (2013a). Interleukins in glioblastoma pathophysiology: Implications for therapy. *British Journal of Pharmacology*, 168(3), 591–606. <https://doi.org/10.1111/bph.12008>
- Yeung, Y. T., McDonald, K. L., Grewal, T., & Munoz, L. (2013b). Interleukins in glioblastoma pathophysiology: Implications for therapy. *British Journal of Pharmacology*, 168(3), 591–606. <https://doi.org/10.1111/bph.12008>
- Zorzan, M., Giordan, E., Redaelli, M., Caretta, A., & Mucignat-Caretta, C. (2015). Molecular targets in glioblastoma. In *Future Oncology* (Vol. 11, Issue 9, pp. 1407–1420). Future Medicine Ltd. <https://doi.org/10.2217/fon.15.22>